基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响

doi:10.11904/j.issn.1002-3070.2022.01.017

Abstract

Abstract: Breast cancer,as the world's highest incidence of cancer,seriously threatens the life and health of women.Luminal A-like breast cancer is the most common subtype of breast cancer,with the characteristics of high degree of cell differentiation and low invasiveness.The study found that the axillary lymph node metastasis rate of Luminal A breast cancer can still reach 26.3%,and the greater the number of lymph node metastases,the lower the 5-year survival rate,so there are still a considerable number of Luminal A breast cancer patients who will have a poor the prognosis.This article mainly reviews the factors affecting the prognosis of Luminal A breast cancer from the aspects of gene expression,polygene detection and biomarkers,so as to provide reference for clinical decision-making and predicting the prognosis of patients.

Key words: Luminal type A, Breast cancer, Prognosis

CLC Number:

R737.9

CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer[J]. Journal of Practical Oncology, 2022, 36(1): 89-93.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/89

References

1 Ferlay J,Colombet M,Soerjomataram I,et al.Cancer statistics for the year 2020:an overview[J].Int J Cancer,2021.
2 Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
3 Hennigs A,Riedel F,Gondos A,et al.Prognosis of breast cancer molecular subtypes in routine clinical care:a large prospective cohort study[J].BMC Cancer,2016,16(1):734.
4 Atahan IL,Yildiz F,Ozyigit G,et al.Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer[J].Acta Oncol,2008,47(2):232-238.
5 Kim HS,Park I,Cho HJ,et al.Analysis of the potent prognostic factors in luminal-type breast cancer[J].J Breast Cancer,2012,15(4):401-406.
6 Xue C,Wang X,Peng R,et al.Distribution,clinicopathologic features and survival of breast cancer subtypes in Southern China[J].Cancer Science,2012,103(9):1679-1687.
7 Kasangian AA,Gherardi G,Biagioli E,et al.The prognostic role of tumor size in early breast cancer in the era of molecular biology[J].PLoS One,2017,12(12):e0189127.
8 Wang F,He W,Qiu H,et al.Lymph node ratio and pN staging show different superiority as prognostic predictors depending on the number of lymph nodes dissected in Chinese patients with luminal A breast cancer[J].Clin Breast Cancer,2012,12(6):404-411.
9 Vinh-Hung V,Joseph SA,Coutty N,et al.Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer[J].Oncologist,2010,15(10):1050-1062.
10 Liu P,Wang Y,Li X.Targeting the untargetable KRAS in cancer therapy[J].Acta Pharm Sin B,2019,9(5):871-879.
11 Hwang KT,Kim BH,Oh S,et al.Prognostic Role of KRAS mRNA Expression in Breast Cancer[J].J Breast Cancer,2019,22(4):548-561.
12 Li Y,Zhang X,Qiu J,et al.Comparisons of p53,KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis[J].J buon,2019,24(6):2361-2368.
13 Schon K,Tischkowitz M.Clinical implications of germline mutations in breast cancer:TP53[J].Breast Cancer Res Treat,2018;167(2):417-423.
14 Williams LA,Butler EN,Sun X,et al.TP53 protein levels,RNA-based pathway assessment,and race among invasive breast cancer cases[J].NPJ Breast Cancer,2018,4(13).
15 Kocak A,Heselmeyer-Haddad K,Lischka A,et al.High levels of chromosomal copy number alterations and TP53 mutations correlate with poor outcome in younger breast cancer patients[J].Am J Pathol,2020,190(8):1643-1656.
16 Fountzilas G,Giannoulatou E,Alexopoulou Z,et al.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting[J].Oncotarget,2016,7(22):32731-32753.
17 Silwal-Pandit L,Vollan HK,Chin SF,et al.TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance[J].Clin Cancer Res,2014,20(13):3569-3580.
18 Aure MR,Vitelli V,Jernström S,et al.Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome[J].Breast cancer research,BCR,2017,19(1):44.
19 Esquela-Kerscher A,Slack FJ.Oncomirs-microRNAs with a role in cancer[J].Nature reviews Cancer,2006,6(4):259-69.
20 McAnena P,Tanriverdi K,Curran C,et al.Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer[J].BMC cancer,2019,19(1):436.
21 McDermott AM,Miller N,Wall D,et al.Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer[J].PLoS One,2014,9(1):e87032.
22 Kornienko AE,Guenzl PM,Barlow DP,et al.Gene regulation by the act of long non-coding RNA transcription[J].BMC Biol,2013,11:59.
23 Marini A,Lena AM,Panatta E,et al.Ultraconserved long non-coding RNA uc.63 in breast cancer[J].Oncotarget,2017,8(22):35669-35680.
24 Syed YY.Oncotype DX breast recurrence score(®):a review of its use in early-stage breast cancer[J].Mol Diagn Ther,2020,24(5):621-632.
25 Ahmed S,Pati S,Le D,et al.The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer[J].J Surg Oncol,2020,122(2):144-154.
26 Audeh W,Blumencranz L,Kling H,et al.Prospective validation of a genomic assay in breast cancer:the 70-gene mammaprint assay and the MINDACT Trial[J].Acta medica academica,2019,48(1):18-34.
27 Li SC,Stucky A,Chen X,et al.Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel[J].Oncotarget,2018,9(70):33290-33301.
28 Fatima A,Tariq F,Malik MFA,et al.Copy number profiling of mammaprint^TM genes reveals association with the prognosis of breast cancer patients[J].Journal of breast cancer,2017,20(3):246-253.
29 Shi YJ,Tsang JY,Ni YB,et al.FGFR1 is an adverse outcome indicator for luminal A breast cancers[J].Oncotarget,2016,7(4):5063-5073.
30 Elsheikh SE,Green AR,Lambros MB,et al.FGFR1 amplification in breast carcinomas:a chromogenic in situ hybridisation analysis[J].Breast Cancer Res,2007,9(2):23.
31 Voutsadakis IA.8p11.23 Amplification in Breast Cancer:Molecular Characteristics,Prognosis and Targeted Therapy[J].J Clin Med,2020,9(10):3079.
32 Bergen ES,Berghoff AS,Steindl A,et al.Androgen receptor is expressed in breast cancer brain metastases[J].Appl Immunohistochem Mol Morphol,2021,29(10):728-733.
33 Wijesinghe HD,Wijesinghe GK,Mansoor Z,et al.Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma[J].BMC women's health,2020,20(1):206.
34 Mooradian AD,Morley JE,Korenman SG.Biological actions of androgens[J].Endocrine reviews,1987,8(1):1-28.
35 Fu WF,Li JJ,Kang SH,et al.The expression,clinicopathologic characteristics,and prognostic value of androgen receptor in breast cancer:a bioinformatics analysis using public databases[J].DNA and cell biology,2020,39(5):864-874.

[1]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[2]	WANG Yuping, SI Meili, SUN Xiaoxia, GUO Yulin. High expression of HPIP in endometrial carcinoma and its significance in the analysis of survival and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 44-48.
[3]	WANG Lina, WANG Le, JIN Hong, LI Qi, CHENG Haiyan. The expression of UBQLN1 in cervical cancer and its effect on prognosis [J]. Journal of Practical Oncology, 2021, 35(6): 506-510.
[4]	CHEN Yixin, SUN Yihua, CHENG Yangyang, HE Kaitong, GUO Ting. Relationship between preoperative inflammation-related indicators and prognosis of patients with resectable gastric cancer [J]. Journal of Practical Oncology, 2021, 35(6): 517-522.
[5]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[6]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[7]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[8]	ZHOU Tianhong, GU Xiuying, YAO Fang, SONG Shuming. Analysis for screening results of breast cancer in Urumqi from 2014 to 2018 [J]. Journal of Practical Oncology, 2021, 35(5): 391-395.
[9]	LU Junrong, WANG Huiwen, HE Dongfeng. Significance of high expression of SALL4 in clinicopathological and prognostic judgment of esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 420-425.
[10]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[11]	QIN Chao, LI Jiang, ZHENG Yadi, WANG Fei, CAO Wei, XU Yongjie, YU Yiwen, ZHAO Liang, YU Xinyang, CHEN Hongda, REN Jiansong, WANG Yong, LI Jing, LI Ni, CHEN Wanqing. Analysis of screening compliance and related factors in high-risk populations of breast cancer in Chinese cities [J]. Journal of Practical Oncology, 2021, 35(4): 291-296.
[12]	GUO Lanwei, ZHANG Shaokai, LIU Shuzheng, ZHENG Liyang, CHEN Qiong, CAO Xiaoqin, SUN Xibin, ZHANG Jiangong. Analysis of compliance with breast cancer screening and its influencing factors in urban areas of Henan province [J]. Journal of Practical Oncology, 2021, 35(4): 307-313.
[13]	YU Youlin, YU Junlin, HU Chaohua, SHEN Xiongshan, LI Weimin, LU Ting, YANG Feng, YANG Qingqing, LIU Chenhao. Analysis for clinical prognostic value of LAYN in thyroid cancer and its influence on infiltration of immune cells [J]. Journal of Practical Oncology, 2021, 35(4): 357-364.
[14]	LIU Wen, QIAO Wenbo. Clinical research status of programmed cell death protein-1 and its ligand in colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(4): 370-375.
[15]	DONG Xiaoping, ZHANG Xue, GUO Dongli, HE Yutong. Research progress on the related factors affecting the prognosis of squamous cell carcinoma of lung [J]. Journal of Practical Oncology, 2021, 35(4): 380-385.

The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments